All In Biotech

Drug Trial Radar · NCT07903701

A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of SIM0811 Injection in Patients With Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,092 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,092

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1. Does SIM0811 improve overall functional outcome, measured by the ability to perform daily activities independently without help 90 days after treatment? 2. What medical problems do participants have when taking SIM0811? Researchers will compare different doses of SIM0811 to a placebo (a look-alike substance that contains no drug) to see if SIM0811 works to treat acute ischemic stroke. Participants will: 1. Receive SIM0811 or a placebo . 2. Receive standard medical care for stroke. On the first day, all participants will also take an aspirin pill or an aspirin placebo to keep the treatment assignment a secret. 3. Stay in the hospital for a few days to undergo medical tests, including CT or MRI scans and blood draws. 4. Return to the clinic for follow-up visits for up to 90 days to check their recovery and overall health.

Conditions

  • Acute Ischemic Stroke AIS

Interventions

  • SIM0811 Dose Level A (Phase II)Drug

    Participants receive SIM0811 Dose Level A.

  • SIM0811 Dose Level B (Phase II)Drug

    Participants receive SIM0811 Dose Level B.

  • SIM0811 Dose Level C (Phase II)Drug

    Participants receive SIM0811 Dose Level C.

  • Placebo(Phase II)Drug

    Participants receive SIM0811 placebo

  • SIM0811(Phase III)Drug

    Participants receive the selected target dose of SIM0811

  • Placebo(Phase III)Drug

    Participants receive SIM0811 placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at Day 90Time frame: Day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.